Phase I Study of LB-100 With Docetaxel in Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01837667
Recruitment Status : Completed
First Posted : April 23, 2013
Last Update Posted : January 24, 2017
Information provided by (Responsible Party):
Lixte Biotechnology Holdings, Inc.